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Abstract
Background—Recently, use of advanced imaging modalities, such as MRI, has increased
dramatically. One novel but still evolving use for MRI is in the diagnosis and clinical staging of
newly diagnosed breast cancer patients. Compared with mammography, MRI is more sensitive,
but less specific, and far more expensive. The purpose of this study is to examine the prevalence
and predictors of MRI use for clinical staging in older women with newly diagnosed breast cancer.
Materials and Methods—SEER-Medicare data were used to identify incident breast cancer
cases between 2003 and 2005. Outpatient Medicare claims data were queried for receipt of breast
MRI. Multivariate logistic regression analyses were performed to examine associations between
receiving MRI and patient demographics, clinical characteristics, and SEER region.
Results—A total of 46,824 patients with breast cancer met inclusion criteria. MRI use increased
from 3.9% of women diagnosed in 2003 to 10.1% of women diagnosed in 2005. In the bivariate
analyses race, urban/rural location, SEER region, poverty level, education level, stage, surgery
type, and tumor size were all significantly associated with receipt of MRI. In the multivariate
analysis, those who were younger, white, living in more metropolitan areas, and living in
wealthier areas were more likely to receive MRI. There was substantial variability in odds of MRI
among different SEER regions.
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Conclusions—Breast MRI for patients with newly diagnosed breast cancer in the SEER-
Medicare population is increasingly common. Ongoing examination of the dissemination of
technology is critical to understanding current practice patterns and to the development and
implementation of future guidelines.
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INTRODUCTION
Breast cancer is the most common cancer and the second leading cause of cancer death
among women in the United States [1]. Mammography and ultrasound are the standard
imaging modalities used to evaluate breast disease. In recent years, magnetic resonance
imaging (MRI) has emerged as a potential adjunct to conventional imaging for selection of
optimal local therapy in women with known breast cancer. MRI is more sensitive than is
conventional mammography for identifying cancer in certain groups, and has been reported
to improve staging of disease in others [2, 3]. Multiple single institution studies suggest that
MRI has been rapidly adopted for use in treatment selection and assisting with surgical
planning [4–6].
However, considerable uncertainty remains about the downstream clinical benefits of
routine use of breast MRI in women with a new cancer diagnosis [7]. This lack of clarity
about the appropriate use of breast MRI in the general population is a quality of care
problem, as defined by the Institute of Medicine (IOM) in 2001 [8]. For women at average
or low risk, MRI may be overused, resulting in increased cost of care and risk of over-
treatment associated with false positive findings. Previous studies have demonstrated that
uncertainty surrounding the utility of a test or treatment is associated with increased
variation in its use [9].
Although case series suggest that breast MRI utilization is increasing, the actual frequency
of utilization in the population at large remains unknown. Such utilization data are important
for both clinicians and policy makers amidst increasing pressures to optimize both cost and
outcomes. This study examines the use of breast MRI in the Medicare population, including
clinical and sociodemographic factors associated with its use. To our knowledge, this is the
first study to investigate this issue in a population-based sample. The goal of this study is to
inform the development and implementation of guidelines for risk-appropriate use of breast
MRI.
MATERIALS AND METHODS
Dataset and Study Cohort
This study used the Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked
database. The SEER-Medicare database is a collaboration between the SEER registries, the
National Cancer Institute (NCI), and the Center for Medicare and Medicaid Services (CMS)
to capture Medicare beneficiaries with an incident cancer diagnosis who live in a SEER
registry area. SEER cases of such patients are then linked to the patients’ Medicare
administrative claims. It is estimated that 97% of the incident cancers of Medicare
beneficiaries in SEER registry areas are captured in the data [10, 11]. This combination of
clinical information with administrative claims allows for longitudinal analysis of oncologic
care and health care resource utilization. As of 2000, the database included 17 population-
based registry areas, comprising 26% of the US population [12].
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Patients with stage 0–IV breast cancer diagnosed between January 1, 2003 and December
31, 2005 were identified in the database. Patients were excluded if they were male; their
diagnosis occurred at the time of death or autopsy; or they were <65- y-old at diagnosis. To
ensure complete claims, the sample was then limited to women enrolled in both Medicare
both Parts A and B for 3 mo prior to and 12 mo after diagnosis, and not enrolled in a
“Medicare Advantage” plan during this same time period.
Analysis
Outpatient insurance claims during the study period were queried to identify receipt of
breast magnetic resonance imaging (MRI). Breast MRI was captured in outpatient Medicare
files using specific American Medical Association Current Procedural Terminology (CPT)
or HCPCS codes (76093-94, 77058-59, C8903-C8908). Inpatient MRIs are variably
captured in Medicare claims, and breast MRI would rarely be employed preoperatively on a
hospitalized patient; therefore we excluded MRIs performed in the inpatient setting.
Definitive surgical management was obtained from SEER records, with additional surgical
information obtained from Medicare claims when possible.
Two categories of variables were examined as factors associated with breast MRI use;
sociodemographic (age, race, year of diagnosis, SEER region, poverty level, urban/rural
residence, and level of education) and clinical (stage, surgery type, and tumor size)
characteristics (Table 1). Because we did not have access to patient-level socioeconomic
variables, area-based data were used to measure these factors. Although these variables are
not merely proxies for individual-level data, they have been shown to be predictive of health
outcomes and are widely used as a measure of socioeconomic status [13]. Area-based
education level was measured using year 2000 National Census Tract data documenting
percent of census tract inhabitants with high-school level education only. Census tract data
were also used to ascertain area-level poverty estimates by examining the percent of
inhabitants living at or below the poverty line. Rural-Urban Continuum Codes for each
county (developed by the United States Department of Agriculture), are used by SEER to
define areas that are more or less metropolitan. These variables were used for area-level
rural/urban information. American Joint Committee on Cancer, 6th edition, stage
information and tumor size (cm) were included as clinical variables. All data for patient-
level, area-level, and clinical independent variables came solely from SEER records.
The main outcome of interest was presence or absence of breast MRI. Bivariate analysis was
performed using χ2 statistical analysis for categorical variables and Student’s t-test for
continuous variables. The independent continuous variables of age, education level, and
poverty level were consolidated into categorical groups (quartiles) for the bivariate and
multivariate analyses. Because of the large overall sample size, we knew a priori that even
small differences in characteristics would achieve statistical significance. Our choice of
variables for the multivariate models was based on both clinical significance and
independent variables’ statistical significance in bivariate analysis. Therefore, for the
bivariate analysis we set the level of significance to P < 0.01. Multivariate analysis was done
using logistic regression modeling with a P value <0.05 indicating statistical significance in
the final model. Analysis was done using STATA ver.11 and results were reported as
percentages, means (except in one case where median was more appropriate), and odds
ratios. The study was reviewed by the institutional review board of the University of North
Carolina and exempted from a full review.
RESULTS
The database includes 87,433 women who received a diagnosis of breast cancer between
January 1, 2003 and December 31, 2005. Of these, 37,073 were excluded because they were
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either enrolled in a Medicare Advantage plan, or did not meet continuous enrollment
criteria. An additional 3534 were excluded because they were <65 y the time of diagnosis.
The number of incident breast cancer cases remained stable over the study period (Table 1).
The mean age of the women at diagnosis was 76.4 y (range 65–107). Additional baseline
characteristics of the study population are presented in Table 1.
Of the 46,824 included cases, 3241 (6.9%) were identified as having undergone at least one
breast MRI. The use of breast MRI increased over time, from 3.9% of patients diagnosed in
2003 to 10.1% of patients diagnosed in 2005 (P < 0.01) (Fig. 1). Breast MRI was performed
a median of 31 d after the date of diagnosis (range 44 d before to 395 d after). Women in the
MRI group were slightly younger than those in the non-MRI group, (mean age 73.1 y versus
76.4 y, P < 0.01). All bivariate analyses reached statistical significance at the level of P <
0.01, and these data are presented in Table 1. In the bivariate analyses, those diagnosed most
recently, younger women, white and Hispanic women, women living in areas of higher
income, and women living in areas with a greater proportion of high school graduates were
most likely to receive breast MRI.
A large proportion of study patients lived in either “big metro” (population > 1 million) or
“metro” (metro areas with population < 1 million) areas as defined by RUCCs (57.3% and
28.5%, respectively), with certain SEER regions more heavily represented in the study
population than others. MRI use was associated with geographic variation: women living in
more metropolitan areas were more likely to receive MRI than were women living in non-
metropolitan areas, and different SEER regions showed marked differences in overall
utilization rate of MRI. The percentage of women receiving MRI ranged from 0.85% in
Hawaii to 18.0% in New Mexico (Fig. 2). For bivariate and multivariate analyses, San
Francisco was used as the referent group because its prevalence of MRI was closest to the
mean for all regions.
Ascertaining the association of MRI use with stage of disease and tumor size is somewhat
problematic because we do not know whether coding for these variables was based on pre-
MRI clinical findings, or influenced by MRI, operative, or postoperative pathologic
findings. Still, we did examine the bivariate relationship between MRI use and stage of
disease and tumor size (Table 1). Although the differences were statistically significant, they
were too small to be clinically meaningful. We preliminarily examined other clinical
features captured in the SEER data that might differ between the MRI and non-MRI groups
and found no clinically important differences between the two groups in tumor histology or
receptor status. Because of this, and the fact that including them did not change the overall
findings of our adjusted model, we did not include these clinical variables in our final
multivariate model.
Similarly, although not the focus of our study, we do report surgical procedure performed.
The average time from diagnosis to first surgical intervention was 39 d (SD = 35). MRI was
performed in 3057 women who underwent cancer directed surgery, 184 who did not
undergo surgery, and 17 with missing data. Overall bivariate analysis of MRI and surgery
type was statisticially significant (Table 1). Bivariate analysis of MRI and subsequent
surgery type was done using only those patients who underwent MRI prior to breast
conservation therapy (BCT) or mastectomy (n = 41,992). There was no clinically significant
difference between receipt of MRI and subsequent surgery performed, with 38.8% of
women undergoing mastectomy in the non-MRI group and 40.8% in the MRI group (P =
0.04).
As in the bivariate analysis, women from wealthier areas were more likely to receive MRI
than were women from impoverished areas. White patients had higher odds of receiving
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MRI than black patients in both bivariate and multivariate analysis. Although in bivariate
analysis Hispanic women were slightly more likely to receive MRI, they were less likely to
receive MRI after incorporating other variables into the model, likely reflecting the effect of
the relationship between geography and ethnicity. However, the differences seen in this
group, as well as the findings in the “other” race category, are limited by sample size and do
not reach statitstical significance in multivariate analysis. Asian women were slightly less
likely to receive MRI, and this difference reached statistical signifiance in both bivariate and
multivariate analysis.
In contrast to the minimal effect of clinical variables on receipt of MRI in our analysis, the
effect sizes for the influence of age, year of diagnosis, and SEER region on the likelihood of
MRI were large (Table 2). Younger patients were most likely to receive MRI. Those
diagnosed in 2005 were almost three times more likely to receive MRI than were those
diagnosed in 2003 (OR 2.88). Adjusted odds ratios among SEER regions ranged from 0.30
in Hawaii to 9.98 in New Mexico. Poverty level and education level were correlated in the
data (r = 0.29, P < 0.001). To eliminate problems of collinearity, we included only poverty
level in the multivariate analysis.
DISCUSSION
Early evidence, including a recent randomized controlled trial (Comparative Effectiveness
of MRI in Breast Cancer, COMICE) [14], suggests routine use of breast MRI in newly
diagnosed breast cancer patients may not improve short-term clinical outcomes such as
reoperation rate, mastectomy rate, or local recurrence rate [4, 5, 14–16]. The likelihood that
use of MRI will improve breast cancer survival is even smaller given the already low rates
of local recurrence. Yet, multiple single-institution studies document increasing utilization
of this technology [4–6, 17–19]. The goal of our study was to provide the first population-
based assessment of breast MRI in breast cancer patients to determine an approximation of
true utilization rates. We also examined clinical and sociodemographic variables associated
with breast MRI use. Our data confirm previously reported single-institution findings, with
an increase in utilization of breast MRI among incident cases from 2003 (3.9%) to 2005
(10.1%).
The overall rate of breast MRI utilization in this study was lower than in the previously cited
single-institution studies for several potential reasons. First, the study time period represents
the early adoption period for breast MRI technology. Second, MRI use would be expected to
be lower in the Medicare population, as most of the commonly proposed indications are for
younger women. Published reports may also be more likely to arise from institutions with
familiarity with the procedure. MRI has been touted as superior to mammography for
women with dense breast tissue who are typically younger [20], meaning that, in our
population of women ages 65 y and older, we would anticipate extremely low rates of breast
MRI utilization.
Several studies demonstrate racial disparities in the receipt of recommended oncologic
treatment in women with breast cancer [21]. In our multivariate model, we too found
differences in the odds of receiving breast MRI by race, although some of this difference
was explained by other factors in the multivariate analysis. While this study was not
designed to focus on disparities or clinical outcomes, it does suggest that novel technologies,
such as breast MRI, may be disparately adopted in different patient populations. The effects
of this varied adoption may result in different outcomes for those who do and do not receive
novel technologies. But if the use of a technology does not confer benefit, the harms of its
disparate use are not straightforward. The degree to which sociodemographic factors
contribute to disparate clinical practices itself varies across geographic region, adding an
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additional layer of complexity. For breast MRI, we may eventually conclude that those who
did not receive the novel technology in fact received more appropriate care. Tracking
whether disparities diminish or increase over time, as well as the consequences of disparities
for outcomes, will be important.
Given the observed clinical similarities between those who received MRI and those who did
not, this study demonstrates two different kinds of variability: differential adoption and
geographic variation. The ways in which technology is differentially adopted are well
studied in a body of literature beginning several decades ago. Variables such as the medical/
training culture, institutional characteristics, specific attributes of the technology, and the
political and economic climate of the time have all been shown to influence adoption of
medical technologies and, specifically, MRI technology [22]. While much of the literature
addressing MRI focuses on acquisition of scanners, it is reasonable to suggest that these
other variables may also contribute to variation in adoption of breast MRI techniques,
especially in the early stages of adoption.
Analyses of Medicare data have frequently noted geographic variation in care [23, 24]. The
etiology has generally been determined to be multifactorial and/or largely unexplained. We
similarly documented considerable differences in MRI utilization among different SEER
regions (Fig. 2). Although SEER region may not be the optimal unit of analysis for
geographic variation, the substantial differences we identified even at this level warrant
further exploration of the potential driving factors for geographic variation in adoption of
this technology.
First and foremost is the desire to deliver high quality care to our patients. Breast MRI has
the potential to be a valuable tool in some situations, and the enthusiasm to expand its
application is understandable. However, we must carefully consider both the benefits and
harms of adopting any new technology while its utility remains unclear. Other influences on
the rapid uptake of MRI include the availability of in-office or free standing imaging centers
and the potential financial incentives for self-referral. The most comprehensive trial to
address the question of spending was the COMICE trial [14]. This trial did not find a
statistically significant difference in the overall cost of care between those who were
randomized to MRI versus those who received no MRI. However, the study was conducted
in the UK and may not be generalizable to the US, where the structure of health care
financing is entirely different and procedure-driven. Still others attribute imaging overuse,
and to some extent, variation in practice, to factors such as defensive medicine, increasing
patient demand for more studies, and lack of accepted guidelines. Guidelines for the use of
MRI in average risk women are still evolving, and differ among issuing groups [25, 26]. As
researchers continue to monitor this technology, we should consider measuring these factors
and assessing their correlation with utilization.
Our study has several limitations. SEER-Medicare data are not entirely nationally
representative. Elderly persons residing in a SEER region are more likely to be non-white,
of higher socioeconomic status, and more urban than are those living in non-SEER regions
[10]. Findings from the data represent the older population, and are unlikely to be
generalizable to the younger population of breast cancer patients, since there are more
potential indications for breast MRI in younger women. It is also possible that elderly
patients with extensive medical comorbidities might be less likely to receive MRI, however,
we feel this is unlikely to account for substantial variation in our population. Specific
comorbidities, such as having a pacemaker, preclude MRI utilization, and this is a potential
limitation of our study. Also, the significant time lag for available SEER-Medicare data
precludes analysis of more recent trends. We expect that more current data will reflect even
Sommer et al. Page 6













higher utilization rates, further strengthening our hypothesis that MRI use is increasing
despite conflicting evidence regarding its utility.
Administrative claims are intended for billing, and must be interpreted with caution, as they
do not always accurately and completely represent clinical findings. For example, those
services not covered by Medicare, such as treatments delivered as part of a clinical trial, are
not represented in the claims data. Although commonly used to measure socioeconomic
status, area-based data are not representative of any one individual living in that area. This
must be considered when making inferences about sociodemographic disparities. Finally,
the majority of analysis of geographic variation in clinical practice, outcomes, and
utilization of resources is done at the health service area (HSA), hospital referral region
(HRR) level, or even at the institutional level, and, ideally, our analysis would have
followed suit. However, the low overall prevalence of breast MRI in many SEER regions
made analysis at a geographic unit smaller than that of the SEER region unreliable. In light
of this limitation, we were unable to conduct a full exploration of the sources of regional
variation in adoption of this technology.
Summary
The standard for appropriate use of breast MRI in women with newly diagnosed breast
cancer is not yet established. In order to encourage efficient and appropriate use of this
technology, evidence-based criteria for breast MRI utilization need to be developed. Our
findings contribute to efforts to understand practice patterns in light of available evidence
that does not support routine use of breast MRI. This study demonstrates that even in the
older population, advanced imaging modalities are being adopted rapidly, variably, and not
necessarily targeted appropriately, as demonstrated by marked differences in utilization
based on geographic region, race, and area socioeconomic status—factors that should not be
related to clinical appropriateness. This is important for both policy makers and clinicians. It
is our hope that this type of population-level analysis will, when combined with primary
data collected from trials and observational studies, encourage more appropriate targeting of
advanced testing to those patients most likely to benefit.
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Percent of incident breast cancer cases receiving MRI by year.
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Percent of incident breast cancer cases receiving breast MRI by SEER region.
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TABLE 1
Subject Demographics and Percent of Patients Receiving Breast MRI
Variable Total n = 46,824 Received MRI n = 3241 (% of total)*
Age (mean) 76.4 73.1 (6.9)
Year
 2003 15,729 607 (3.9)
 2004 15,777 1094 (6.9)
 2005 15,318 1540 (10.1)
Race
 White 39,672 2832 (7.1)
 Black 3383 133 (3.9)
 Hispanic 1836 152 (8.3)
 Asian/Pacific Isl. 1589 92 (5.8)
 Other/unknown 344 32 (9.3)
SEER urban/rural
 Big metro 26,835 2289 (8.5)
 Metro 13,320 732 (5.5)
 Urban 2744 109 (4.0)
 Less urban 3259 95 (2.9)
 Rural 666 16 (2.4)
Poverty level† (n = 43,958)
 1st Quartile ($$$) 10,973 1048 (9.6)
 2nd Quartile 11,002 856 (7.8)
 3rd Quartile 10,985 712 (6.5)
 4th Quartile ($) 10,998 436 (4.0)
Education level† (43,962)
 1st Quartile (highest) 10,876 1182 (10.9)
 2nd Quartile 11,043 798 (7.2)
 3rd Quartile 11,070 655 (5.9)
 4th Quartile (lowest) 10,973 418 (3.8)
Stage
 0/in situ 7,694 496 (6.5)
 I 19,019 1318 (6.9)
 II 11,556 887 (7.7)
 III 3361 295 (7.2)
 IV 2137 82 (3.8)
 Unknown 3057 163 (6.9)
Surgery type
 None 4,036 184 (4.6)
 Breast conservation 26,005 1901 (7.3)
 Mastectomy 16,444 1139 (6.9)
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Variable Total n = 46,824 Received MRI n = 3241 (% of total)*
 Unknown/missing 339 17 (5.0)
Tumor size
 0/micro 3133 151 (4.8)
 0–2 26,495 1886 (7.1)
 2–5 11,173 775 (6.9)
 >5 2724 221 (8.1)
 Unknown 3299 208 (7.1)
[Source: SEER-Medicare data 2003–2005].
*
Determined by χ2 test for categorical and student’s t-test for continuous variables (P < 0.01 for all analyses).
†
Grouped in quartiles by author.
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TABLE 2
Unadjusted and Adjusted Odds of Breast MRI
Variable Unadjusted OR (95% CI) Adjusted OR (95% CI)*
Age
 65–69 1.0 1.0
 70–74 0.74 (0.68–0.81) 0.72 (0.65–0.79)
 75–79 0.51 (0.46–0.56) 0.49 (0.44–0.54)
 80–84 0.32 (0.28–0.36) 0.29 (0.26–0.33)
 85–90 0.18 (0.15–0.22) 0.17 (0.14–0.21)
 >90 0.08 (0.05–0.13) 0.08 (0.05–0.12)
Year
 2003 1.0 1.0
 2004 1.86 (1.68–2.06) 1.91 (1.71–2.12)
 2005 2.78 (2.53–3.07) 2.88 (2.60–−3.19)
Race
 White 1.0 1.0
 Black 0.53 (0.45–0.64) 0.75 (0.61–0.91)
 Hispanic 1.17 (0.99–1.39) 0.84 (0.69–1.01)
 Asian/Pacific Isl. 0.80 (0.65–0.99) 0.71 (0.56–0.89)
 Other/unknown 1.33 (0.92–1.92) 1.10 (0.75–1.65)
SEER urban/rural
 Big metro 1.0 1.0
 Metro 0.62 (0.57–0.68) 0.62 (0.55–0.69)
 Urban 0.44 (0.36–0.54) 0.41 (0.32–0.51)
 Less urban 0.32 (0.26–0.40) 0.54 (0.42–0.70)
 Rural 0.26 (0.16–0.43) 0.76 (0.44–1.30)
Poverty level
 1st Quartile 1.0 1.0
 2nd Quartile 0.78 (0.71–0.86) 0.83 (0.75–0.92)
 3rd Quartile 0.64 (0.58–0.71) 0.72 (0.65–0.80)
 4th Quartile 0.39 (0.35–0.44) 0.47 (0.41–0.53)
[Source: SEER-Medicare data 2003–2005].
*
Adjusted for age, year of dx, race, urban/rural, poverty level, and SEER region using logit model.
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